FertilAI – a company utilising artificial intelligence (AI) to optimise the fertility journey – has raised $4.5 million to support market expansion, personnel, and reinforcing R&D efforts.
FertilAI provides doctors with AI-driven patient insights to aide clinical decision-making and optimise clinic workflow and efficiency.
The company’s AI-based Fertilane platform integrates with clinic electronic medical records (EMRs) to improve predictability, clinical outcomes, and the patient experience throughout the fertility journey.
This includes identifying optimal embryo transfer timing and optimising decision-making throughout the stimulation cycle to ovulation tracking, supporting timed intercourse, and facilitating intrauterine insemination (IUI).
“The fertility market is growing at an unprecedented rate and becoming a pressing issue on a global scale,” said Raissa Hacohen, managing partner of Longevity Venture Partners.
“We invested in FertilAI because the team’s expertise is uniquely suited to solve this market need and its platform has already demonstrated significant traction in the market.”
“We are absolutely delighted to support Rohi and his Tier 1 team on their mission to tangibly improve clinical outcomes with FertilAI’s next-generation algorithm,” said Helena Cavell, principal at investor Redseed.
“The investment is a significant validation of our mission and vision,” said Rohi Hourvitz, CEO of FertilAI.
“Everything we do is focused on providing the opportunity to create families more quickly and affordably. We want patients to achieve pregnancy much earlier in the process, instead of struggling through multiple rounds of treatment at thousands of dollars each.”
